Literature DB >> 30944658

Association between TP53 genetic polymorphisms and the methylation and expression of miR-34a, 34b/c in colorectal cancer tissues.

Hak Hoon Jun1, Kyubum Kwack2, Keun Hee Lee1, Jung Oh Kim2, Han Sung Park2, Chang Soo Ryu2, Jeong Yong Lee2, Daeun Ko3, Jong Woo Kim1, Nam Keun Kim2.   

Abstract

Colorectal cancer (CRC) is one of the most common types of cancers, as evidenced by the >1.2 million patient diagnoses and 600,000 mortalities globally each year. Recently, the microRNA (miR/miRNA)-34 miRNA precursor family was revealed to participate in the tumor protein (TP)-53 pathway, which is frequently involved in CRC. Furthermore, the expression of miR-34 is reportedly regulated by DNA methylation. Accordingly, the present study investigated the correlation between the methylation status of miR-34 miRNAs and miR-34 expression in paired CRC tumor and normal tissues. The methylation status of miR-34a and miR-34b/c was determined using the MethyLight assay, and the expression of miR-34a and miR-34b/c in the same paired tissues was analyzed by reverse transcription-quantitative polymerase chain reaction. The results revealed significantly elevated miR-34a (P=0.012) and miR-34b/c (P<0.0001) methylation levels in tumor tissues when compared with normal tissues, whereas only the expression of miR-34b/c differed (P=0.005) between the paired tissues. In addition, an association between TP53 haplotypes and miR-34 family expression levels was observed. The miR-34a methylation levels in the TP53 PIN A1A1 (48.56±36.49) and TP53 MSP GG (49.00±36.44) genotypes were increased in the tumor tissues when compared with normal tissues. In conclusion, it was determined that miR-34 promoter methylation and TP53 polymorphisms may be associated with CRC pathogenesis.

Entities:  

Keywords:  DNA methylation; expression; microRNA-34a; microRNA-34b; microRNA-34c; single nucleotide polymorphism; tumor protein 53

Year:  2019        PMID: 30944658      PMCID: PMC6444414          DOI: 10.3892/ol.2019.10092

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  7 in total

1.  Tumor-derived exosomes encapsulating miR-34a promote apoptosis and inhibit migration and tumor progression of colorectal cancer cells under in vitro condition.

Authors:  Maryam Hosseini; Kaveh Baghaei; Davar Amani; Masoumeh Ebtekar
Journal:  Daru       Date:  2021-08-17       Impact factor: 4.088

2.  MicroRNA-145-5p regulates the proliferation of epithelial ovarian cancer cells via targeting SMAD4.

Authors:  Jie Zhou; Xiyi Zhang; Weiling Li; Yuanyuan Chen
Journal:  J Ovarian Res       Date:  2020-05-04       Impact factor: 4.234

3.  Anti-Colorectal Cancer Mechanisms of Formononetin Identified by Network Pharmacological Approach.

Authors:  Lei Zhang; Yizhen Gong; Shuai Wang; Feng Gao
Journal:  Med Sci Monit       Date:  2019-10-14

Review 4.  Sexual Dimorphism in Colon Cancer.

Authors:  Maria Abancens; Viviana Bustos; Harry Harvey; Jean McBryan; Brian J Harvey
Journal:  Front Oncol       Date:  2020-12-09       Impact factor: 6.244

5.  Prognostic impact of miR-34b/c DNA methylation, gene expression, and promoter polymorphism in HPV-negative oral squamous cell carcinomas.

Authors:  Gordana Supic; Debora Stefik; Nemanja Ivkovic; Ahmad Sami; Katarina Zeljic; Sasa Jovic; Ruzica Kozomara; Danilo Vojvodic; Srboljub Stosic
Journal:  Sci Rep       Date:  2022-01-25       Impact factor: 4.379

6.  Seminal plasma miRNAs in Klinefelter syndrome and in obstructive and non-obstructive azoospermia.

Authors:  Federica Finocchi; Marianna Pelloni; Giancarlo Balercia; Francesco Pallotti; Antonio F Radicioni; Andrea Lenzi; Francesco Lombardo; Donatella Paoli
Journal:  Mol Biol Rep       Date:  2020-06-01       Impact factor: 2.742

7.  Novel regulation of miR-34a-5p and HOTAIR by the combination of berberine and gefitinib  leading to inhibition of EMT in human lung cancer.

Authors:  Fang Zheng; Jing Li; ChangJu Ma; XiaoJuan Tang; Qing Tang; JingJing Wu; XiaoSu Chai; Jianhui Xie; Xiao-Bo Yang; Swei Sunny Hann
Journal:  J Cell Mol Med       Date:  2020-04-05       Impact factor: 5.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.